NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Sara Witting Christensen WenLine NederbyRikke Fredslund AndersenTorben Frøstrup HansenChrista Haugaard NyhusOle HilbergAnders JakobsenTorben Frøstrup HansenPublished in: British journal of cancer (2023)
Combining NKA and ctDNA status after one cycle of treatment was prognostic in patients with NSCLC treated with PD-1/PD-L1 inhibitors.